Abstract

 CADTH recommends that Libtayo should be reimbursed by public drug plans for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) previously treated with a hedgehog pathway inhibitor (HHI) if certain conditions are met.
 Libtayo should only be covered to treat adult patients who have laBCC that cannot be cured by surgery or radiation and are unlikely to benefit from further HHI therapy. Patients should have good performance status.
 Libtayo should only be reimbursed if it is prescribed by a clinician with expertise in treating cancer and managing side effects. The price of Libtayo must be lowered to be cost-effective and affordable.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
